SG11201407387UA - Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders - Google Patents
Use of ghrelin receptor inverse agonists or antagonists for treating sleep disordersInfo
- Publication number
- SG11201407387UA SG11201407387UA SG11201407387UA SG11201407387UA SG11201407387UA SG 11201407387U A SG11201407387U A SG 11201407387UA SG 11201407387U A SG11201407387U A SG 11201407387UA SG 11201407387U A SG11201407387U A SG 11201407387UA SG 11201407387U A SG11201407387U A SG 11201407387UA
- Authority
- SG
- Singapore
- Prior art keywords
- rule
- international
- lllll
- iii
- treating sleep
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title abstract 4
- 239000002469 receptor inverse agonist Substances 0.000 title abstract 4
- 208000019116 sleep disease Diseases 0.000 title abstract 4
- 102000000393 Ghrelin Receptors Human genes 0.000 title abstract 3
- 108010016122 Ghrelin Receptors Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000012004 Ghrelin Human genes 0.000 abstract 1
- 101800001586 Ghrelin Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655177P | 2012-06-04 | 2012-06-04 | |
| US201361812416P | 2013-04-16 | 2013-04-16 | |
| PCT/IB2013/054177 WO2013182933A1 (en) | 2012-06-04 | 2013-05-21 | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407387UA true SG11201407387UA (en) | 2014-12-30 |
Family
ID=48700662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407387UA SG11201407387UA (en) | 2012-06-04 | 2013-05-21 | Use of ghrelin receptor inverse agonists or antagonists for treating sleep disorders |
Country Status (16)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105175272A (zh) * | 2015-08-31 | 2015-12-23 | 吴玲 | 制备r-5-溴-1-氨基茚满的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| RU2366428C2 (ru) * | 2002-12-20 | 2009-09-10 | Дзе Маклин Хоспитал Корпорейшн | Соединения для нормализации цикла сна/бодрствования |
| US20050171132A1 (en) | 2003-09-26 | 2005-08-04 | Zhili Xin | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists |
| US20090149512A1 (en) * | 2004-05-14 | 2009-06-11 | Novo Nordisk A/S | Use of Ghrelin Antagonists to the Treatment of Certain CNS Diseases |
| JP2009542809A (ja) * | 2006-07-12 | 2009-12-03 | メルク エンド カムパニー インコーポレーテッド | グレリン受容体アンタゴニストとしての置換ピラゾール |
| US8309530B2 (en) * | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
| PH12012501800A1 (en) * | 2010-03-19 | 2012-12-10 | Pfizer | 2,3 dihydro- 1h - inden- 1 - yl -2,7 -diazaspirol [ 3.5 ] nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor |
-
2013
- 2013-05-21 ES ES13732257T patent/ES2716303T3/es active Active
- 2013-05-21 WO PCT/IB2013/054177 patent/WO2013182933A1/en active Application Filing
- 2013-05-21 MX MX2014014813A patent/MX2014014813A/es unknown
- 2013-05-21 AU AU2013273263A patent/AU2013273263B2/en not_active Ceased
- 2013-05-21 KR KR1020147034009A patent/KR101708989B1/ko not_active Expired - Fee Related
- 2013-05-21 CA CA2874196A patent/CA2874196C/en not_active Expired - Fee Related
- 2013-05-21 HK HK15103243.2A patent/HK1202459A1/xx unknown
- 2013-05-21 CN CN201380029429.7A patent/CN104334193A/zh active Pending
- 2013-05-21 JP JP2015515606A patent/JP6165852B2/ja not_active Expired - Fee Related
- 2013-05-21 US US14/398,800 patent/US9370516B2/en active Active
- 2013-05-21 SG SG11201407387UA patent/SG11201407387UA/en unknown
- 2013-05-21 BR BR112014029577A patent/BR112014029577A2/pt active Search and Examination
- 2013-05-21 EP EP13732257.4A patent/EP2854856B1/en not_active Not-in-force
- 2013-05-21 RU RU2014146109/15A patent/RU2600895C2/ru not_active IP Right Cessation
-
2014
- 2014-11-24 IL IL235883A patent/IL235883A0/en unknown
- 2014-11-25 ZA ZA2014/08672A patent/ZA201408672B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9370516B2 (en) | 2016-06-21 |
| IL235883A0 (en) | 2015-01-29 |
| KR101708989B1 (ko) | 2017-02-21 |
| AU2013273263B2 (en) | 2017-08-24 |
| JP2015518876A (ja) | 2015-07-06 |
| EP2854856A1 (en) | 2015-04-08 |
| KR20150013236A (ko) | 2015-02-04 |
| EP2854856B1 (en) | 2019-01-23 |
| RU2600895C2 (ru) | 2016-10-27 |
| US20150119381A1 (en) | 2015-04-30 |
| CA2874196A1 (en) | 2013-12-12 |
| CN104334193A (zh) | 2015-02-04 |
| MX2014014813A (es) | 2015-02-12 |
| RU2014146109A (ru) | 2016-07-27 |
| HK1202459A1 (en) | 2015-10-02 |
| BR112014029577A2 (pt) | 2017-06-27 |
| JP6165852B2 (ja) | 2017-07-19 |
| ES2716303T3 (es) | 2019-06-11 |
| AU2013273263A1 (en) | 2014-11-27 |
| WO2013182933A1 (en) | 2013-12-12 |
| ZA201408672B (en) | 2016-09-28 |
| CA2874196C (en) | 2016-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201407548UA (en) | Treatment of amd using aav sflt-1 | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201811491YA (en) | Quinazoline and indole compounds to treat medical disorders | |
| SG11201408140QA (en) | Crystalline forms of an androgen receptor modulator | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201407397WA (en) | Formulations and methods for vaginal delivery of antiprogestins | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof |